Pharvaris to Participate in BioCapital Europe

ZUG, Switzerland, March 04, 2021 (GLOBE NEWSWIRE) -- Pharvaris PHVS, a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced that Berndt Modig, chief executive officer and co-founder of Pharvaris, will participate in BioCapital Europe, to be held virtually on March 11, 2021.

Participation Details:

Title: "Shaping the New Biotech Reality – Key Lessons from COVID" Panel Presentation

Date/Time: March 10, 2021, 18:30 CET (12:30 p.m. EST)

Title: Pharvaris Corporate Presentation

Date/Time: March 11, 2021, 14:50 CET (8:50 a.m. EST)

The virtual presentation will be available for 30 days on the Pharvaris website at https://ir.pharvaris.com/news-events/events-presentations.

About Pharvaris

Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. For more information, visit https://pharvaris.com/.

Investor Contact

Chad Rubin, Solebury Trout

crubin@soleburytrout.com

Media Contact

Maggie Beller, Russo Partners, LLC

maggie.beller@russopartnersllc.com

+1-646-942-5631



Primary Logo

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!